Drug Profile
Varicella zoster virus vaccine live - GlaxoSmithKline
Alternative Names: Chickenpox vaccine - GlaxoSmithKline; GSK-208133; VarilrixLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Osaka University
- Developer GlaxoSmithKline
- Class Varicella vaccines; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Varicella zoster virus infections
Most Recent Events
- 12 Apr 2021 Discontinued - Phase-II for Varicella zoster virus infections (In infants, Prevention) in Hungary, Czech Republic (SC)
- 12 Apr 2021 Discontinued - Phase-III for Varicella zoster virus infections (In infants, Prevention) in Mexico, Thailand, United Kingdom, Estonia, Germany (SC)
- 01 Oct 2016 GlaxoSmithKline Biologicals completes a phase III trial in Varicella zoster virus infections (In infants, Prevention) in Germany, Estonia, Mexico, Thailand and the UK (SC) (NCT02570126)